Calidi Biotherapeutics announced FDA clearance for a clinical trial (CLD-101) targeting high-grade glioma, as detailed in their press release dated September 30, 2024.
AI Assistant
CALIDI BIOTHERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.